Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.
Opinion Statement: There has been rapid progress in the use of targeted therapies for ALK-positive which has led to improve dramatically PFS and OS in the metastatic ALK-rearranged NSCLC patients. There are several molecules now available (crizotinib, ceritinib, brigatinib, alectinib, and lorlatinib...
| Publicado en: | Current Treatment Options in Oncology Vol. 20; no. 10 |
|---|---|
| Autores principales: | , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Oct2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |